Sihuan Pharmaceutical Announces Share Purchase Under Share Award Scheme Amidst Record Growth

Key Highlights

• Share Purchase: On 21 April 2026, Sihuan Pharmaceutical Holdings Group Ltd. (“Sihuan Pharmaceutical” or the “Company”) announced that the trustee of its Share Award Scheme purchased 3,000,000 shares on the market. This represents approximately 0.0328% of the Company’s total issued shares (excluding treasury shares), at an average price of HK\$1.3567 per share.
• Purpose: The purchase is in line with the Company’s 2022 Share Award Scheme, designed to incentivize and retain core management and talent.
• Outstanding Financial Performance: For the year 2025, Sihuan Pharmaceutical reported total revenue of RMB2,618.0 million, a robust 37.7% year-on-year increase. The Company also swung from loss to profit, recording a net profit of RMB185.4 million, marking a significant turnaround and entry into an accelerated phase of profitable growth.
• Rapid Growth in Medical Aesthetics: The Company’s medical aesthetics segment generated RMB1,485.3 million in revenue, surging 99.6% year-on-year and accounting for 57% of total revenue—the first time this segment surpassed the 50% mark.
• Global Expansion: Through investment in Swiss company Suisselle, Sihuan Pharmaceutical has entered the European medical aesthetics market, leveraging an “overseas investment + resource integration” model to drive faster global expansion.
• Innovative Drug Commercialization: The innovative drug segment saw revenue more than double year-on-year, supported by successful product launches and inclusion in the National Reimbursement Drug List (NRDL).
• Strategic Alignment: The share purchase under the award scheme is intended to stabilize the core team and reinforce long-term incentives, aligning management’s interests with shareholders and the Company’s high-growth trajectory.

Potential Price-Sensitive Information for Shareholders

• Return to Profitability: Sihuan Pharmaceutical’s transition from losses to a positive net profit in 2025 may improve investor sentiment and support a higher valuation.
• Explosive Growth in Medical Aesthetics: The medical aesthetics business is now the Company’s largest revenue driver, reflecting strong market demand and effective commercialization of self-developed flagship regenerative products.
• International Strategy: The Company’s entry into the European market via Suisselle could accelerate global revenue diversification and raise Sihuan Pharmaceutical’s profile as an international player.
• Ongoing Product Pipeline Commercialization: The doubling of innovative drug revenue and new product launches, along with NRDL inclusion, signals sustainable high growth and value realization.
• Share Award Scheme: The use of treasury to support the share award scheme—particularly after strong financial results—demonstrates management’s confidence in the Company’s future and may help align interests, potentially leading to improved operational performance and share price appreciation.

Company Overview

Listed on the Main Board of the Hong Kong Stock Exchange since 2010, Sihuan Pharmaceutical positions itself as an innovation-led international pharmaceutical and medical aesthetics company. It boasts an independent and leading R&D platform, a robust global product pipeline, strong registration capabilities, an efficient and low-cost full dosage production platform, and a mature sales system. The Company’s dual-engine strategy focuses on both medical aesthetics and biopharmaceuticals, aiming to become a leading player in China’s rapidly expanding healthcare sector.

Board and Governance

The Board currently comprises Chairman and Executive Director Dr. Che Fengsheng, Deputy Chairman and CEO Dr. Guo Weicheng, Dr. Zhang Jionglong, Ms. Chen Yanling, Ms. Miao Guili, and independent non-executive directors Mr. Tsang Wah Kwong, Dr. Zhu Xun, and Mr. Wang Guan.

Investor Takeaways

• The Company’s strong financial results and transition to profitability, coupled with the rapid growth of its medical aesthetics and innovative drugs businesses, provide a solid foundation for long-term value creation.
• The share purchase under the award scheme is a strong signal of management’s confidence in the Company’s prospects and may help support the share price.
• The international expansion into Europe and the ongoing commercialization of new products position Sihuan Pharmaceutical as a potential leader in both the domestic and global markets.

Disclaimer: The information provided in this article is for informational purposes only and does not constitute investment advice. Investors are advised to conduct their own research or consult a professional adviser before making any investment decisions. The Company’s past performance is not indicative of future results. All forward-looking statements are subject to risks and uncertainties.

View SIHUAN PHARM Historical chart here